Bonesupport Holding
BONESUPPORT Holding AB is a Swedish parent company for a medical technology group focused on orthobiologics. The group develops and commercializes injectable bioceramic bone graft substitutes under the CERAMENT platform for use in orthopedic procedures, with sales concentrated in the US and Europe.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueInjectable bioceramic bone graft products used to fill bone voids and remodel into host bone.
CERAMENT G and CERAMENT V products designed for bone infection and contaminated cases.
CERAMENT BVF used in orthopedic reconstruction where drug elution is not required.
Training, evidence generation, and surgeon support that help adoption of CERAMENT.
Customers
BONESUPPORT sells primarily to hospitals, orthopedic surgeons, and healthcare systems that treat bone defects, fractures, and bone infections. In the US, sales are made both directly and through distributors, including OrthoPediatrics for pediatric access, while in Europe the company uses a mix of direct sales, hybrid coverage, and specialist distributors. Demand is tied to adoption in specific orthopedic procedures such as trauma, foot and ankle, revision arthroplasty, and spine.
Buy CERAMENT for orthopedic procedures involving bone voids, trauma, and infection management.
Use the products in surgery and influence adoption based on clinical outcomes and evidence.
Access CERAMENT through OrthoPediatrics for children’s orthopedic cases.
Purchase or facilitate sales in selected markets to extend geographic reach and coverage.
Strategy
BONESUPPORT’s strategy centers on expanding CERAMENT adoption in prioritized orthopedic segments, especially Foot & Ankle, Trauma, Revision Arthroplasty, and Spine. The company also emphasizes clinical and health-economic evidence, commercial execution, and preparation for new indications to broaden the platform over time.
Concentrating on high-value procedure areas improves sales efficiency and clinical relevance.
Spine extends the CERAMENT platform into another large orthopedic use case.
Clinical publications and health-economic data support surgeon adoption and reimbursement discussions.
Geography
BONESUPPORT is headquartered in Lund, Sweden and operates through subsidiaries across Europe and the US. The company’s commercial footprint is concentrated in the US and major European markets such as Germany, the UK, Sweden, Denmark, and Benelux, with additional coverage in Australia, Canada, Italy, Norway, Spain, South Africa, and other ROW markets. Geography matters because the business relies on local sales coverage, distributor relationships, and regulatory access in each market.
Risks
BONESUPPORT is exposed to adoption risk because its products depend on surgeon acceptance, clinical evidence, and reimbursement dynamics in orthopedic care. The company also faces regulatory, intellectual property, product liability, currency, and tariff-related risks typical for a medical device business with international sales and cross-border supply chains.
- Slow market acceptance of CERAMENTImpact: HighLikelihood: Medium
Revenue depends on surgeons and hospitals adopting a new orthopedic treatment standard.
Exposure - Regulatory and product approval riskImpact: HighLikelihood: Medium
Medical device and combination-product requirements can delay or block launches.
- Product liability and insurance riskImpact: HighLikelihood: Medium
Implantable orthopedic products can create claims if outcomes or safety are challenged.
- Intellectual property riskImpact: MediumLikelihood: Medium
CERAMENT depends on patents and protection against competing products or disputes.
- Foreign exchange riskImpact: MediumLikelihood: Medium
Revenues and expenses are denominated mainly in USD, GBP and EUR versus SEK reporting.
Exposure - Tariff and trade riskImpact: Medium
US import tariffs can increase cost of goods and reduce segment economics.
Exposure: United States imports
Accounting
Judgemental itemsThe company must decide whether distributors are agents or principals, which changes gross versus net presentation.
Impact: Sales commissions and fees, revenue timing
OrthoPediatrics sales include return rights that require ongoing assessment of control and expected returns.
Impact: Revenue and provisions
Performance share programs and share swap agreements are measured at fair value and can move earnings.
Impact: Operating expenses and financial items
Lease liabilities depend on the marginal borrowing rate and lease term judgments.
Impact: Balance sheet and depreciation/interest expense
Recoverability assumptions can affect deferred tax assets and expected credit losses.
Impact: Tax assets and impairment allowances
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026